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Abstract 34 
Self-home BP monitoring is recommended to guide clinical decisions on hypertension and is 35 
used worldwide for cardiovascular risk management. People usually make their own 36 
decisions when purchasing BP devices, which are often made online. If patients purchase 37 
non-validated devices (those not proven accurate according to internationally accepted 38 
standards), hypertension management may be based on inaccurate readings resulting in 39 
under- or over-diagnosis or treatment. This study aimed to evaluate the number, type, 40 
percentage validated and cost of home BP devices available online. A search of online 41 
businesses selling devices for home BP monitoring was conducted. Multinational companies 42 
make worldwide deliveries, so searches were restricted to BP devices available for one nation 43 
(Australia) as an example of device availability through the global online marketplace. 44 
Validation status of BP devices was determined according to established protocols. 59 online 45 
businesses, selling 972 unique BP devices were identified. These included 278 upper-arm 46 
cuff devices (18.3% validated), 162 wrist-cuff devices (8.0% validated) and 532 wrist-band 47 
wearables (0% validated). Most BP devices (92.4%) were stocked by international e-48 
commerce businesses (e.g. eBay, Amazon), but only 5.5% were validated. Validated cuff BP 49 
devices were more expensive than non-validated devices: median (interquartile range) of 50 
101.1 (75.0, 151.5) versus 67.4 (30.4, 112.8) AUD. Non-validated BP devices dominate the 51 
online marketplace and are sold at lower cost than validated ones, which is a major barrier to 52 
accurate home BP monitoring and cardiovascular risk management. Before purchasing a BP 53 
device, people should check it has been validated at https://www.stridebp.org 54 
 55 
Keywords. blood pressure determination; medical device legislation; device approval; 56 
wearable electronic devices 57 
58 
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 58 
Introduction  59 
High blood pressure (BP) is the number one risk factor for cardiovascular disease and 60 
mortality worldwide.1 Accurate BP measurement is important because identification and 61 
effective treatment of high BP will reduce the risk of future adverse cardiovascular events.2 62 
Recent data support the use of home BP for hypertension management because it provides 63 
clinical information that is prognostically superior to in-clinic BP and enhances medication 64 
adherence with lower BPs.3-5 This evidence has led to the widespread recommendation for 65 
home BP to be used for confirming the diagnosis of hypertension and treatment titration.6, 7  66 
When undertaking home BP monitoring, patients are advised to only use BP devices 67 
that have been confirmed to be validated for accuracy.8 However, there is no regulatory 68 
requirement for manufacturers of BP devices to adhere to specific validation protocols, nor 69 
publicly share the accuracy performance results.9 This can lead to the marketing and sale of 70 
BP devices with poor accuracy,10, 11 and thus potentially contributing to inferior quality 71 
hypertension management and patient health outcomes. To redress this, it is recommended 72 
that validation testing be performed by investigators that are independent from manufacturers 73 
and aligned with established scientific protocols.12 Yet, according to unpublished data, less 74 
than 15% of BP devices have undergone such validation testing.13   75 
Online shopping is used for purchasing goods and services including medical devices. 76 
To our knowledge there are no peer reviewed published data regarding the online availability 77 
of BP devices that may be used for home monitoring which have been validated according to 78 
recognized international protocols. We evaluated the number, type, percentage validated 79 
(accurate) and cost of home BP devices available to purchase online.  80 
Methods 81 
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The data that support the findings of this study are available from the corresponding author 82 
upon reasonable request. 83 
Study overview. This study was designed to provide evidence on the number of validated 84 
and non-validated BP devices available for purchase by online consumers. Accordingly, the 85 
search was restricted to BP devices available in one country (Australia), as an example in the 86 
global online marketplace. It was not possible to conduct a worldwide analysis because the 87 
online purchase and delivery of goods crosses international borders, and although large 88 
multinational companies have country-specific websites, they may also offer shipping to 89 
many other countries. In the first step, a search of online businesses that sell BP devices was 90 
conducted by a single reviewer (RD) between 5 and 22 December 2018. Variations of the 91 
phrase “blood pressure monitor buy online Australia” were searched and the first five pages 92 
of results were examined. The online websites of Australian pharmacies were also examined 93 
because these businesses are known to sell BP devices (full details in the Online-only 94 
Methods). Upper arm cuff, wrist cuff or wrist-band wearable (cuff-less, multi-function 95 
activity trackers) devices purporting to measure BP in an automatic or semi-automatic 96 
manner were included in the search because all these types of devices may be purchased by 97 
consumers seeking to measure BP at home. Devices targeted only for professional use (e.g. in 98 
a hospital or general practice) or those requiring manual auscultation for BP measurement 99 
were excluded (see Online-only Methods). In the second step, the validation status of each 100 
identified BP device was determined via a search of four online databases (Medaval, 101 
PubMed, Google and Dabl Educational Trust). Two blinded reviewers (RD, DSP) conducted 102 
the search between 18 January and 5 February 2019 and discordant validation results were 103 
discussed with an adjudicator (JES). The study was ruled exempt from ethical review by the 104 
Tasmanian Human Research Ethics Committee according to sections 2.1.7 and 5.1.22 of the 105 
Australian National Statement on Ethical Conduct in Human Research, 2007 (Updated 2018).  106 
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Determining BP device validation status. A device was deemed to be validated if: 1) it had 107 
passed a validation study according to an internationally recognized validation protocol for 108 
measurement of BP in the general population,14-18 and the results were published in a peer-109 
reviewed journal or peer-reviewed database, or; 2) the core technology was claimed by the 110 
manufacturer to be identical to a device that had previously passed a validation study 111 
(referred to as ‘claimed equivalence’ herein).19  See Online-only Methods, Table S1 and 112 
Figure S1 for more detail.  113 
Statistical analyses. Chi-square and Fisher Exact tests were used to determine if there were 114 
statistically significant differences in the number of validated or equivalent BP devices 115 
available according to the type of device and the business category (pharmacy, medical, 116 
Australian general retail or e-commerce, as per Online-only Methods). The cost of the BP 117 
devices was reported as median (interquartile range (IQR)) because the distribution of device 118 
costs was skewed. A sensitivity analysis of the number of validated devices was performed 119 
after removal of BP devices with no, or incomplete, device information (based on 120 
manufacturer name and model number). Mann-Whitney U tests were used to determine 121 
whether the costs of BP devices were significantly different based on the type of device and 122 
validation status. P values <0.05 were considered statistically significant. Analysis was 123 
conducted using R version 3.5.1. 124 
Results 125 
Number and types of validated home BP devices. 4301 items available for purchase from 126 
59 unique online businesses were screened and 1501 BP devices were recorded after 127 
irrelevant search results and duplicates devices from the same online businesses were 128 
excluded (Figure 1). After duplicates across all businesses were excluded, 972 unique BP 129 
devices remained including 278 upper arm cuff, 162 wrist cuff and 532 wrist-band wearable 130 
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devices. Of the 972 devices, 6.6% were validated (n=26, 2.7%)20-39 or claimed equivalence to 131 
a previously validated device (n=38, 3.9%). 132 
Of the 278 unique upper-arm cuff devices, 51 (18.3%) were validated (n=18, 6.8% peer-133 
reviewed in a journal; n=1, <1% peer-reviewed and published on Dabl Educational Trust 134 
database, http://www.dableducational.org/Publications/2015/ESH-135 
IP%202010%20Validation%20of%20Microlife%20%20BPA3PC.pdf) 20-45 or claimed equivalence 136 
(n=32, 11.5%; Figure 2). Accompanying publicly available documents for claimed 137 
equivalence were found for 19 of the 32 devices. Of the 162 unique wrist cuff devices, 13 138 
(8.0%) were validated (n=7, 4.3%)37, 40-45 or claimed equivalence (n=6, 3.7%; Figure 2). 139 
Accompanying documents for claimed equivalence were found for four of the six devices. 140 
The number of upper arm cuff devices validated or claimed equivalence was significantly 141 
greater than wrist cuff devices (χ2=8.0, p=0.0048). None of the 532 wrist-band wearable 142 
devices were validated. Listings of all validated BP devices and those devices that claimed 143 
equivalence are in the Tables S2-S3, respectively. 144 
Number and type of validated devices according to business categories. The 59 online 145 
businesses included: 16 pharmacies, 20 medical, five Australian general retail and 18 e-146 
commerce websites. There were 124, 79, 12 and 1286 devices available from each business 147 
category respectively (Tables S4-S7). Upper arm BP cuff devices accounted for 90.5%, 148 
87.8% and 71.4% of the unique devices sold by pharmacies, medical and Australian general 149 
retailers respectively. Wrist cuff BP devices accounted for the remainder. 100% of wrist-band 150 
wearables were available from e-commerce businesses and these accounted for 56.5% of 151 
devices available from these websites. The remaining devices available from e-commerce 152 
businesses were upper arm cuff BP devices (26.5%) and wrist cuff BP devices (17%). 153 
Additional results relating to business categories are in the Online-only Results and Figure 154 
S2. 155 
HYPE202014719-R2 
 8 
Device cost according to validation status. The median device cost was 47.09, interquartile 156 
range (IQR; 31.01 to 86.99 AUD; 32.08 IQR 21.14 to 59.30 USD). Upper-arm cuff BP 157 
devices were significantly more expensive than wrist cuff BP devices (85.45 IQR 48.67 to 158 
128.75 versus 50.68 IQR 23.99 to 94.77 AUD, p<0.0001; 58.25 IQR 33.18 to 87.77 versus 159 
34.55 IQR 16.35 to 64.61 USD), irrespective of validation status. Upper-arm and wrist cuff 160 
BP devices that were validated or claimed equivalence were significantly more expensive 161 
than non-validated BP devices (101.14 IQR 75.00 to 151.50 versus 67.37 IQR 30.40 to 162 
112.83 AUD, p<0.0001; 68.95 IQR 51.13 to 103.28 versus 45.93 IQR 20.72 to 76.92 USD). 163 
Validated or claimed equivalence BP devices were also significantly more expensive than 164 
non-validated BP devices when upper-arm (104.00 IQR 75.90 to 174.00 versus 80.25 IQR 165 
43.00 to 122.02 AUD, p=0.00019; 70.90 IQR 51.74 to 118.62 versus 54.71 IQR 29.31 to 166 
83.18 USD) and wrist cuff (87.32 IQR 67.05 to 110.00 versus 44.47 IQR 23.98 to 94.00 167 
AUD, p=0.0040; 59.53 IQR 45.71 to 74.99 versus 30.32 IQR 16.35 to 64.08 USD) BP 168 
devices were analysed separately (Figure S3).  169 
Validation status according to available device information. Complete BP device 170 
information (manufacturer name and model number) was listed by the online businesses for 171 
529 (54.4%) BP devices. Upper arm cuff devices more often had complete information 172 
available, while incomplete information (only manufacturer name or model number) was 173 
most common in wrist-band wearables. There was no information (only generic descriptions) 174 
available more often for wrist cuff BP devices. All devices that were validated or claimed 175 
equivalence had complete BP device information available (Table S8).  176 
Discussion 177 
This study has several notable findings relating to the availability of home BP devices 178 
for online purchase in Australia. First, there was an enormous quantity of devices purporting 179 
to measure BP available for consumers to purchase (n=978). Less than a third of these were 180 
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upper-arm cuff BP devices, of which only 18.3% from 278 were confirmed to have been 181 
clinically validated or claimed equivalence. Second, there were a large number of wrist cuff 182 
BP devices of which only a small percentage were confirmed validated or equivalent to 183 
another validated BP device (8.0% from 162). Third, more than half of the unique BP devices 184 
available for purchase were wrist-band wearables (532 from 972 total devices) for which 185 
none were validated. Importantly, the e-commerce websites, including large global 186 
companies (e.g. eBay, Amazon), stocked most of the BP devices available for purchase 187 
(92.5%), but only 5.5% of these were validated. Lastly, validated BP devices were 188 
significantly more expensive than non-validated BP devices. These findings reveal several 189 
issues with global implications. Most urgently, public health education is needed to counsel 190 
people and healthcare providers on how to purchase appropriately validated BP devices. 191 
International guidelines recognize the value of measuring BP outside the clinical 192 
environment, and most advocate the use of self-home BP monitoring to confirm diagnosis 193 
and for ongoing management of raised BP.6, 7 For this purpose, people are advised to acquire 194 
upper arm BP devices that have been validated according to an internationally accepted 195 
scientific protocol, with results published in the peer-reviewed literature.8, 46, 47 Unfortunately, 196 
there is little practical guidance provided to consumers on how to purchase appropriately 197 
validated BP devices (nor information for clinicians on what to advise patients), and our 198 
findings show that people are faced with an overabundance of poor quality BP devices 199 
online. Since only 6.5% of the 278 upper arm cuff BP devices had been validated with the 200 
results published in a peer-reviewed journal, this means that only 18 devices from all 972 201 
available online (1.9%) would be recommended by guidelines for people to purchase for 202 
home BP monitoring.6, 46, 47 A further 32 devices were classed as equivalent based on 203 
technological characteristics critical to the BP measurement method being substantially 204 
equivalent to a previously validated (predicate) device.19 This means that if a new device is 205 
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deemed equivalent to a predicate device, then the previous validation study is accepted as 206 
evidence of accuracy of the new device. However, this has been criticized as a loophole in 207 
regulatory procedures that allows clearance of BP devices of unknown accuracy without 208 
independent verification.48 A resulting confusion is that manufacturers may claim clinical 209 
validation of a BP device based on equivalence, even though this may be disputed by 210 
independent scientific bodies. Thus, it is probable that the inclusion of equivalent devices in 211 
our list of validated BP devices will have overestimated the number of accurate BP devices 212 
available for online purchase in Australia. Altogether our observations imply a strong 213 
likelihood for people unwittingly buying BP devices that are not recommended for clinical 214 
use and are more likely to be inaccurate.10, 11 The extent to which this could adversely 215 
influence best-practice clinical care through incorrect home BP values being provided to 216 
doctors is not known.  217 
Our data on the prevalence of non-validated BP devices is similar to that estimated by 218 
internal company data from Medaval among more than 3000 upper arm and wrist cuff BP 219 
devices, for which 87.5% had no independent data on proven clinical accuracy.13 Although 220 
our study was restricted to the online purchasing environment within one country, the 221 
findings may be more broadly generalizable, particularly across countries with similar 222 
regulation of health devices as Australia and where there is globally connected online trading 223 
through e-commerce providers. To our knowledge this is the first study to recognize the 224 
preponderance of low price, wrist-band wearable BP devices being marketed for online sale. 225 
In terms of validation of these devices, the IEEE Standard for Wearable Cuff-less Blood 226 
Pressure Measuring Devices was developed in 2014,49 but has not been widely used. 227 
Therefore, investigators often use traditional validation protocols to determine the accuracy 228 
of wrist-band cuff-less BP devices.50 Whether these devices are being used by patients to 229 
measure home BP and report results to health care providers is not known and was not tested 230 
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in this study but emphasizes the need for clinicians to clarify the type of BP devices being 231 
used by their patients. 232 
Most online businesses do not specifically identify which home BP devices have 233 
passed validation testing according to independent protocols separate from internal processes 234 
used by manufacturers.51 This creates a highly challenging marketplace for consumers where 235 
there is little emphasis on the importance of accuracy amongst marketing information. To our 236 
knowledge, only one study of home BP device owners has examined this issue and found that 237 
less than 1% of people purchasing a home BP device cited accuracy as a reason for making 238 
the purchase. Moreover, most people made a decision to purchase a home BP device based 239 
on ease of use or learnings from an advertisement.10 Altogether our findings indicate that 240 
these problems need to be solved by widespread public health education to counsel people 241 
and healthcare providers on how to purchase appropriately validated BP devices. This is 242 
relevant to all consumers of BP devices, including individuals, health care providers, 243 
businesses, non-government and government organizations. Efforts in this regard are already 244 
underway9, 52 and include the development of online listings of BP devices that have 245 
undergone independent validation testing,53 which can be freely accessed to help people 246 
make informed purchasing decisions (see Table 1 for a list of web addresses). 247 
There are some study limitations. Data was only recorded from online businesses and 248 
this may have underestimated the amount of BP devices available to consumers through 249 
traditional retailers selling BP devices without an online presence. Organizations such as the 250 
United States Food and Drug Administration may hold information on BP device validation 251 
that is not publicly released. Because BP device validation status was obtained from external 252 
(non-government/regulatory) sources there remains the possibility that some validated 253 
devices may have been recorded as non-validated. However, the study was designed to 254 
replicate the online consumer experience and because this information was not publicly 255 
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available, it would not have influenced the overall study conclusions relating to consumer 256 
exposure to online BP device purchasing choices. Sales data and the number of people that 257 
buy validated versus non-validated devices is unknown and could not be addressed in this 258 
study. Nevertheless, high accessibility and low costs of non-validated devices is potentially 259 
concerning because these are stocked by large, well-known e-commerce businesses. The 260 
analysis was restricted to a specific time period within a rapidly evolving online market that 261 
will be subject to change. As an example, in the time since the search was completed, a 262 
validated oscillometric wrist-wearable device has come to market, although this is not yet 263 
available in Australia.54 The availability of different cuff sizes is also important for the 264 
accurate measurement of BP, but it was beyond the scope of this study to assess this issue. 265 
Finally, the study did not test differences in accuracy between validated and non-validated 266 
devices. However, previous studies suggest that non-validated devices are less accurate than 267 
validated ones.10, 11  268 
In conclusion, this study has shown that most upper-arm and wrist cuff home BP devices and 269 
all the wrist-band wearable (cuff-less) devices available for purchase online in Australia are 270 
non-validated and are cheaper than validated devices. The preponderant online availability of 271 
non-validated wrist-band wearable BP devices is a concern because these are not trustworthy 272 
for diagnosis or follow-up of raised BP. Most of the BP devices sold online should not be 273 
used for clinical decision making, however, it is probable that they are being used for this 274 
purpose. These findings could have major implications for best-practice care of people 275 
related to high BP and emphasize the importance of widespread public education and 276 
advocacy in the area as well as regulation of the device industry to improve the availability of 277 
validated BP devices. 278 
Perspectives 279 
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Most BP devices available for online purchase and use by patients for self-home BP 280 
monitoring have not been tested for accuracy according to internationally accepted standards. 281 
Before purchasing or using a BP device, people and health care providers should check that 282 
the device has passed international scientific validation standards at the STRIDE BP website 283 
(www.stridebp.org) or others listed in Table 1. 284 
Health care providers managing hypertension using home BP values should check with their 285 
patients that they are using an upper arm cuff BP device and that it has been appropriately 286 
validated. Patients should not use wrist-band wearable devices to monitor home BP, as none 287 
are validated. Education, advocacy and strengthened regulatory processes are urgently 288 
required for the global improvement in BP device accuracy standards.  289 
Additional research is needed to determine the extent to which non-validated BP devices are 290 
being used for home BP monitoring and its impact on cardiovascular outcomes. 291 
 292 
293 
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Novelty and significance 
What Is New?  
• Most BP devices available online for self-home BP monitoring have not been 
validated for accuracy. 
• Non-validated BP devices were more likely to be available from e-commerce 
websites and were cheaper. 
What Is Relevant?  
• From nearly one thousand BP devices available for online purchase, only a small 
percentage (<7%) were validated for accuracy. Non-validated devices were more 
likely to be wrist cuff or wrist-band wearable devices, available from e-commerce 
businesses and cheaper than validated devices. 
• Non-validated BP devices are more likely to be inaccurate, thus these findings 
represent a barrier to accurate home BP monitoring and cardiovascular risk 
management. 
Summary 
This study has shown that non-validated upper-arm cuff, wrist cuff and wrist-band wearable 
BP devices dominate the online marketplace. Education, advocacy and strengthened 
regulatory processes are required for the global improvement in BP device accuracy 
standards. 
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Figure legends 
Figure 1. Flow chart of the number of blood pressure (BP) devices available to 
Australian online consumers. From 972 unique BP devices, only a small number were 
validated or claimed equivalence to another validated BP device. 
Figure 2. Proportion of validated, equivalent or non-validated blood pressure (BP) 
devices across all devices available for purchase online in Australia. A device was 
defined as equivalent when there was a claim that the technology was identical to previously 
validated BP device.  
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Table 1. Summary of international entities and the web addresses to listings of blood 
pressure devices that have been independently assessed for accuracy according to 
scientific validation protocols 
Entity holding a listing of validated 
blood pressure devices 
Web address 
STRIDE BP https://stridebp.org/  
British and Irish Hypertension Society https://bihsoc.org/bp-monitors/ 
Hypertension Canada https://hypertension.ca/hypertension-and-
you/managing-hypertension/measuring-
blood-pressure/devices/  
German Hypertension Society 
(in German) 
https://www.hochdruckliga.de/messgeraete-
mit-pruefsiegel.html  
Japanese Society of Hypertension 
(in Japanese) 
http://www.jpnsh.jp/com_ac_wg1.html   
Medaval https://medaval.ie/  
dabl Educational Trust  
(no longer actively updated) 
http://www.dableducational.org/  
American Medical Association Validated 
Device Listing 
Under development 
 


